AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients-Reference-Cited by-同舟云学术

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

Published:2016-11-02 Issue:1 Volume:2 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Bottai Giulia,Raschioni Carlotta,Székely Borbála,Di Tommaso Luca,Szász Attila M,Losurdo Agnese,Győrffy Balázs,Ács Balázs,Torrisi Rosalba,Karachaliou Niki,Tőkés Tímea,Caruso Michele,Kulka Janina,Roncalli Massimo,Santoro Armando,Mantovani Alberto,Rosell Rafael,Reis-Filho Jorge S,Santarpia Libero

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/npjbcancer201633.pdf

Reference46 articles.

1. Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683–692 (2010).

2. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938–1948 (2010).

3. Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30, 1879–1887 (2012).

4. Turner, N. C. & Reis-Filho, J. S. Tackling the diversity of triple-negative breast cancer. Clin. Cancer Res. 19, 6380–6388 (2013).

5. Perou, C. M. Molecular stratification of triple-negative breast cancers. Oncologist 16, 61–70 (2011).

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into multidrug resistance mechanisms: Exploring distinct miRNAs as prospective therapeutic agents in triple negative breast cancer;Gene Reports;2024-12

2. Chromosomal instability as an architect of the cancer stemness landscape;Frontiers in Cell and Developmental Biology;2024-09-13

3. High-motility pro-tumorigenic monocytes drive macrophage enrichment in the tumor microenvironment;2024-07-18

4. AXL receptor as an emerging molecular target in colorectal cancer;Drug Discovery Today;2024-06

5. Mesenchymal–epithelial transition and AXL inhibitor TP-0903 sensitise triple-negative breast cancer cells to the antimalarial compound, artesunate;Scientific Reports;2024-01-03